ArticleBritish journal of cancer2013

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

M Beloueche-Babari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.